Lawmakers in several states are considering bills that would restrict pharmacy compounding under the banner of safety. Indiana lawmakers have the opportunity to protect patient care access by passing SB 282 as it is currently amended.
Past iterations of SB 282 would have denied patients access to compounded GLP-1 medication, even when a prescriber determines that a compounded preparation is necessary for them. These proposals are often described as targeting counterfeit drugs or bad actors. But in practice, they would make it harder for licensed pharmacies to provide medications that many patients rely on when standard drugs don’t work or aren’t available.
Thanks to a concerted effort, including more than 1,300 messages sent via our previous advocacy campaign from patients and prescribers to Indiana senators, the Indiana State Senate passed an amended version of SB 282 that does not threaten patient access to compounded medications. A huge thank-you to everyone who sent messages to their Indiana senators. Yes, it made a difference!
Now, as it moves through the State House, we have to keep it that way.
.png?width=908&height=106&name=Layer_1%20(1).png)
The amended version of SB 282 that passed out of the Senate gives the Indiana Board of Pharmacy much-needed oversight over med spas.
The bill also requires compounding pharmacies and outsourcing facilities to comply with federal laws and regulations (as they should, and as they are already doing).
Language that negatively affected patient access to compounded medications was effectively removed.
Lawmakers should pass SB 282 as currently amended and then focus on enforcing existing laws against illegal drug sales, while preserving access to lawful, patient-specific pharmacy compounding.
Whether you are a patient or physician, join thousands of voices to tell your experience with compounding.
